SuperworthAkari Therapeutics Plc EPS AKTX
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- $0.00
- Latest quarter, Q2 FY26
- $0.00
- Fiscal year 2025
- $0.00
Akari Therapeutics Plc's earnings per share was $0.00 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.00.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.00 | n/a |
| FY2024 | $0.00 | n/a |
| FY2023 | $0.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.00 | n/a | $0.00 | |
| Q1 FY26 | $0.00 | n/a | $0.00 | |
| Q4 FY25 | $0.00 | n/a | $0.00 | |
| Q3 FY25 | $0.00 | n/a | $0.00 | |
| Q2 FY25 | $0.00 | n/a | $0.00 | |
| Q1 FY25 | $0.00 | n/a | $0.00 | |
| Q4 FY24 | $0.00 | n/a | $0.00 | |
| Q3 FY24 | $0.00 | n/a | $0.00 | |
| Q2 FY24 | $0.00 | n/a | $0.00 | |
| Q1 FY24 | $0.00 | n/a | $0.00 | |
| Q4 FY23 | $0.00 | n/a | $0.00 | |
| Q3 FY23 | $0.00 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Akari Therapeutics Plc's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| AKTXAkari Therapeutics Plc | $0.00 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ZVRAZevra Therapeutics | $0.93 | |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| ARVNArvinas | $0.16 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| PCRXPacira BioSciences | $0.35 | |
| Peer median | $0.85 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Akari Therapeutics Plc
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.